➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Dow
AstraZeneca
McKinsey
Medtronic

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RIOMET ER

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Riomet Er

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00087516 ↗ Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) Completed Merck Sharp & Dohme Corp. Phase 3 2004-06-01 The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
NCT00443755 ↗ Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed National Center for Research Resources (NCRR) Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 ↗ Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 ↗ Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed Takeda Pharmaceuticals North America, Inc. Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Riomet Er

Condition Name

Condition Name for Riomet Er
Intervention Trials
Insulin Resistance 4
Type 2 Diabetes Mellitus 4
Type 2 Diabetes 3
Diabetes 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Riomet Er
Intervention Trials
Diabetes Mellitus 10
Diabetes Mellitus, Type 2 7
Insulin Resistance 4
Metabolic Syndrome X 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Riomet Er

Trials by Country

Trials by Country for Riomet Er
Location Trials
United States 93
South Africa 4
Mexico 4
Puerto Rico 3
Russian Federation 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Riomet Er
Location Trials
Ohio 6
Pennsylvania 5
North Carolina 4
New York 4
Colorado 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Riomet Er

Clinical Trial Phase

Clinical Trial Phase for Riomet Er
Clinical Trial Phase Trials
Phase 4 8
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Riomet Er
Clinical Trial Phase Trials
Recruiting 12
Completed 9
Not yet recruiting 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Riomet Er

Sponsor Name

Sponsor Name for Riomet Er
Sponsor Trials
Merck Sharp & Dohme Corp. 4
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
Takeda 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Riomet Er
Sponsor Trials
Other 37
Industry 19
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Dow
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.